Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06934343 · ClinicalTrials.gov registry record
Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data
A clinical trial of Non-Small Cell Lung Cancer, sponsored by University of Utah.
- Recruiting
- Registry status
- 144,400
- Enrollment target
- 1
- Study location
NCT06934343: Recruiting study of Non-Small Cell Lung Cancer, sponsored by University of Utah.
NCT06934343 is a study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by University of Utah. The registered enrollment target is 144,400 participants, above the 334-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (43134% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06934343, a study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- 144,400 participants
- Enrollment target
- 1
- Study location
Study Summary
This research will leverage machine learning (ML) and causal inference techniques applied to real-world data (RWD) to generate evidence that personalizes treatment strategies for patients with advanced non-small cell lung cancer (aNSCLC). Rather than influencing regulatory decisions or clinical guidelines, the goal of this trial is to refine treatment selection among existing therapeutic options, ensuring that care is tailored to individual patient characteristics. Additionally, by generating real-world evidence, these findings will inform the design and implementation of future clinical trials. Importantly, the methodological advancements will establish a pipeline that extends beyond aNSCLC, facilitating the identification of optimal dynamic treatment regimes (DTRs) for other complex diseases.
Primary Outcome
Mortality is the primary concern in aNSCLC care. This study will track survival from the initiation of first-line therapy to death or the last follow-up, whichever occurs first. OS will be censored at the last recorded date in the electronic health records.
Conditions Studied
Study Locations (1)
Utah
- Huntsman Cancer Institute at the University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144,400 participants |
| Start Date | 2024-09-01 |
| Est. Completion | 2026-03 |
What NCT06934343 shows while recruiting
NCT06934343 is an observational study that tracks outcomes without assigning an intervention. Its 144,400 participants enrollment target places it among the larger protocols in the corpus, above the 334-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (43134% higher).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06934343 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT06934343 about?
NCT06934343 is a clinical study titled "Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data". This research will leverage machine learning (ML) and causal inference techniques applied to real-world data (RWD) to generate evidence that personalizes treatment strategies for patients with advanced non-small cell lung cancer (aNSCLC). Rather than influencing regulatory decisions or clinical guid...
What is the current status of trial NCT06934343?
This trial is currently recruiting. The enrollment target is 144,400 participants. The study started on 2024-09-01. Estimated completion is 2026-03.
What conditions does trial NCT06934343 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
Who is sponsoring clinical trial NCT06934343?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06934343 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06934343's enrollment target sits among peer trials
144,400 1st of 454 higher than 454 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT05994482 · 130,000 participants
Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study
- NCT02693509 · 128,026 participants
Get With The Guidelines-Heart Failure Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI